Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, announced the closing of a $100 million oversubscribed Series A financing round. The funding round was co-led by ARCH Venture Partners and Sofinnova Investments, as well as Third Rock Ventures and Seaport founder PureTech Health. Seaport appointed Daphne Zohar as Founder, CEO and a member of the Board of Directors, and Steven M. Paul, M.D., as founder and Chair of the Board of Directors.
Seaport is accelerating a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph Technology Platform, utilizing the lymphatic system to create new medicines based on clinically validated mechanisms. The funding will support the rapid advancement of Seaport’s clinical-stage pipeline of first and sophisticated medicines and further development of the Glyph platform, which has demonstrated clinical proof-of-concept.
The company was built on a proven development strategy and is led by the team that created and advanced the groundbreaking drug candidate KarXT (xanomeline-trospium), which is now poised to be the first new class of medicine in over 50 years for patients living with schizophrenia. Daphne Zohar, the CEO of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics. Under Zohar’s leadership, PureTech’s R&D engine led to 28 new medicines, including two that received U.S. FDA clearance and a third (KarXT) filed for FDA approval.
Dr. Paul, Founder and Chair of the Seaport Board of Directors, is also the former CEO and Chair of the Board of Directors of Karuna Therapeutics, which Bristol Myers Squibb recently acquired. He is also the former President of Research and Development at Eli Lilly, where he oversaw the development of CNS drugs like Zyprexa, Cymbalta, and xanomeline, which were initially demonstrated to have anti-psychotic and pre-cognitive properties.
All of the programs in Seaport’s pipeline are based on the Glyph platform, which was designed to enable and enhance oral bioavailability, avoid first-pass metabolism, and reduce hepatotoxicity and other side effects to advance active drugs that were previously held back by those limitations. And Seaport’s most advanced therapeutic candidate is SPT-3001, an oral prodrug of allopregnanolone, an endogenous neurosteroid, in development for the treatment of anxious depression.
Allopregnanolone demonstrated therapeutic benefit in a range of neuropsychiatric conditions, but it is only approved as an intravenous infusion, which has limited the scope of its clinical use. With the Glyph platform, SPT-300 retains the activity and potency of endogenous allopregnanolone in an oral form and has the potential to capture the breadth of the natural biological response. In the Phase 2a clinical trial, SPT-300 demonstrated proof-of-concept in a validated clinical model of anxiety in healthy volunteers.
Seaport’s pipeline also includes SPT-3202, a novel prodrug of agomelatine being advanced for the treatment of Generalized Anxiety Disorder – which uses the Glyph platform to bypass first-pass metabolism by the liver and has the potential to lower its effective dose, reduce liver exposure, and eliminate the need for liver function monitoring that has held back agomelatine. And SPT-348, a prodrug of a non-hallucinogenic neuroplastogen in development for the treatment of mood and other neuropsychiatric disorders, leverages Glyph to create a potential first-in-class treatment with improved pharmacokinetics and tolerability compared to conventional psychedelics. Beyond the programs, Seaport has multiple discovery and preclinical programs underway.
The additional members joining Seaport’s Board of Directors are Robert Nelsen (Managing Partner and Co-founder of ARCH Venture Partners), James Healy, M.D., Ph.D. (Managing Partner of Sofinnova Investments), Eric Elenko, Ph.D. (Co-founder and President of PureTech and Co-inventor of KarXT), and Bharatt Chowrira, Ph.D. (newly appointed CEO of PureTech). Courtney Wallace (Venture Partner at Third Rock Ventures) is joining as a Board Observer.
KEY QUOTES:
“Major depression and anxiety disorders are among the most common, disabling, and potentially fatal of all medical conditions. Current standard-of-care treatments provide inadequate relief for far too many patients. Seaport’s pipeline of investigational antidepressants and anxiolytics is well-positioned to more effectively treat these disorders and to help millions of people and their families. Given the historically low success rates within neuropsychiatric drug development, precisely solving the previous limitations of clinically validated mechanisms improves the probability of success and enables us to significantly accelerate development.”
– Steven M. Paul M.D.
“We are dedicated to bringing first and best-in-class medicines to those who suffering from depression, anxiety, and other neuropsychiatric disorders. I’m excited to deliver on this mission along with a stellar team of senior leaders and investors.”
– Daphne Zohar, Founder and CEO of Seaport Therapeutics
“I’m thrilled to be partnering again with this outstanding team, led by Daphne and Steve, to change the lives of people with neuropsychiatric disorders. We were the lead investors in Karuna’s Series A and Series B financing rounds, and I’m excited to partner with these strong leaders again to deliver on Seaport’s proven strategy and robust pipeline and bring important new medicines to patients.”
– Robert Nelsen, Co-founder and Managing Director of ARCH Venture Partners
“Seaport has the potential to meaningfully change the lives of patients with neuropsychiatric disorders. We’ve had the pleasure of knowing Steve and Daphne for a number of years as one of the investors in Karuna, and we believe this team has the unique expertise to help solve the challenges of treating serious mental health conditions. I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”
– James Healy, M.D., Ph.D., Managing Partner at Sofinnova Investments
